Killer immunoglobulin-like receptor ligand HLA-Bw4 protects against multiple sclerosis

Annals of Neurology

Volumn 65, Issue 6, 2009, Pages 658-666

  Lorentzen, Åslaug R ^a,b   Karlsen, Tom H ^b   Olsson, Marita ^c,d   Smestad, Cathrine ^e   Mero, Inger Lise ^b,e   Woldseth, Bente ^b,e   Sun, Ji Yao ^f   Senitzer, David ^f   Celius, Elisabeth G ^e   Thorsby, Erik ^b   Spurkland, Anne ^g   Lie, Benedicte A ^b   Harbo, Hanne F ^a,e  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

HLA B ANTIGEN; HLA BW4; HLA DR ANTIGEN; HLA-BW4; HLA-DRB1 ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; CHILD; COMPARATIVE STUDY; FEMALE; GENETICS; HETEROZYGOTE DETECTION; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; MULTIPLE SCLEROSIS; PHYSIOLOGY; PROTEIN BINDING;

ADOLESCENT; ADULT; CHILD; FEMALE; HETEROZYGOTE DETECTION; HLA-B ANTIGENS; HLA-DR ANTIGENS; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PROTEIN BINDING; RECEPTORS, KIR; YOUNG ADULT;

EID: 67650052034     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21695     Document Type: Article

References (46)

1. Jersild C, Svejgaard A, Fog T. HL-A antigens and multiple sclerosis. Lancet 1972;1:1240-1241.
2. Naito S, Namerow N, Mickey MR, et al. Multiple sclerosis: association with HL-A3. Tissue Antigens 1972;2:1-4.
3. Lincoln MR, Montpetit A, Cader MZ, et al. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat Genet 2005;37:1108-1112. (Pubitemid 41486664)
4. Oksenberg JR, Baranzini SE, Sawcer S, et al. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet 2008;9:516-526. (Pubitemid 351861542)
5. Fogdell-Hahn A, Ligers A, Gronning M, et al. Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease. Tissue Antigens 2000; 55:140-148. (Pubitemid 30103439)
6. Harbo HF, Lie BA, Sawcer S, et al. Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. Tissue Antigens 2004;63: 237-247.
7. Yeo TW, De Jager PL, Gregory SG, et al. A second major histocompatibility complex susceptibility locus for multiple sclerosis. Ann Neurol 2007;61:228-236. (Pubitemid 46557347)
8. Brynedal B, Duvefelt K, Jonasdottir G, et al. HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PLoS ONE 2007;2:e664.
9. Vivier E, Tomasello E, Baratin M, et al. Functions of natural killer cells. Nat Immunol 2008;9:503-510. (Pubitemid 351560519)
10. van Bergen J, Thompson A, van der SA, et al. Phenotypic and functional characterization of CD4 T cells expressing killer Iglike receptors. J Immunol 2004;173:6719-6726.
11. Orange JS, Ballas ZK. Natural killer cells in human health and disease. Clin Immunol 2006;118:1-10. (Pubitemid 43012040)
12. Lunemann JD, Munz C. Do natural killer cells accelerate or prevent autoimmunity in multiple sclerosis? Brain 2008;131: 1681-1683. (Pubitemid 351957469)
13. Morandi B, Bramanti P, Bonaccorsi I, et al. Role of natural killer cells in the pathogenesis and progression of multiple sclerosis. Pharmacol Res 2008;57:1-5.
14. Hammarberg H, Lidman O, Lundberg C, et al. Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells. J Neurosci 2000;20:5283-5291. (Pubitemid 30457725)
15. Takahashi K, Aranami T, Endoh M, et al. The regulatory role of natural killer cells in multiple sclerosis. Brain 2004;127: 1917-1927. (Pubitemid 39150251)
16. Airas L, Saraste M, Rinta S, et al. Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. Clin Exp Immunol 2008;151:235-243.
17. Saraste M, Irjala H, Airas L. Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta. Neurol Sci 2007;28:121-126. (Pubitemid 47039837)
18. Boyton RJ, Altmann DM. Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease. Clin Exp Immunol 2007;149:1-8. (Pubitemid 46897116)
19. Karlsen TH, Boberg KM, Olsson M, et al. Particular genetic variants of ligands for natural killer cell receptors may contribute to the HLA associated risk of primary sclerosing cholangitis. J Hepatol 2007;46:899-906.
20. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005;5:201-214. (Pubitemid 40364822)
21. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231. (Pubitemid 13158528)
22. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
23. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33: 1444-1452. (Pubitemid 14237132)
24. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005;64:1144-1151.
25. Sun JY, Gaidulis L, Miller MM, et al. Development of a multiplex PCR-SSP method for killer-cell immunoglobulin-like receptor genotyping. Tissue Antigens 2004;64:462-468. (Pubitemid 39312727)
26. Moesta AK, Norman PJ, Yawata M, et al. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol 2008;180:3969-3979.
27. Thananchai H, Gillespie G, Martin MP, et al. Cutting edge: allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J Immunol 2007;178: 33-37. (Pubitemid 46033585)
28. Stern M, Ruggeri L, Capanni M, et al. Human leukocyte antigens A23, A24, and A32 but not A25 are ligands for KIR3DL1. Blood 2008;112:708-710.
29. Dudbridge F. Pedigree disequilibrium tests for multilocus haplotypes. Genet Epidemiol 2003;25:115-121. (Pubitemid 37064867)
30. Single RM, Martin MP, Gao X, et al. Global diversity and evidence for coevolution of KIR and HLA. Nat Genet 2007;39: 1114-1119. (Pubitemid 47342436)
31. Ahmad T, Neville M, Marshall SE, et al. Haplotypespecific linkage disequilibrium patterns define the genetic topography of the human MHC. Hum Mol Genet 2003;12: 647-656. (Pubitemid 36372491)
32. Blomhoff A, Olsson M, Johansson S, et al. Linkage disequilibrium and haplotype blocks in the MHC vary in an HLA haplotype specific manner assessed mainly by DRB1*03 and DRB1*04 haplotypes. Genes Immun 2006;7:130-140. (Pubitemid 43336055)
33. Nejentsev S, Howson JM, Walker NM, et al. Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A. Nature 2007;450:887-892.
34. Eike MC, Becker T, Humphreys K, Olsson M, Lie BA. Conditional analyses on the T1DGC MHC dataset: novel associations with type 1 diabetes around HLA-G and confirmation of HLA-B. Genes Immun 2009;10:56-67.
35. Shi FD, Van KL. Reciprocal regulation between natural killer cells and autoreactive T cells. Nat Rev Immunol 2006;6:751-760.
36. Hamerman JA, Ogasawara K, Lanier LL. NK cells in innate immunity. Curr Opin Immunol 2005;17:29-35. (Pubitemid 40094010)
37. Corthay A. A three-cell model for activation of naive T helper cells. Scand J Immunol 2006;64:93-96. (Pubitemid 44034312)
38. Anfossi N, Doisne JM, Peyrat MA, et al. Coordinated expression of Ig-like inhibitory MHC class I receptors and acquisition of cytotoxic function in human CD8+ T cells. J Immunol 2004;173:7223-7229. (Pubitemid 39628158)
39. Robinson J, Waller MJ, Stoehr P, et al. IPD - the Immuno Polymorphism Database. Nucleic Acids Res 2005;33: D523-D526. (Pubitemid 40207929)
40. O'Connor GM, Guinan KJ, Cunningham RT, et al. Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells. J Immunol 2007;178:235-241. (Pubitemid 46033606)
41. Gardiner CM, Guethlein LA, Shilling HG, et al. Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism. J Immunol 2001;166:2992-3001. (Pubitemid 33117294)
42. Thomas R, Yamada E, Alter G, et al. Novel KIR3DL1 alleles and their expression levels on NK cells: convergent evolution of KIR3DL1 phenotype variation? J Immunol 2008;180: 6743-6750.
43. Yawata M, Yawata N, Draghi M, et al. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med 2006;203:633-645.
44. Ramagopalan SV, Deluca GC, Degenhardt A, et al. The genetics of clinical outcome in multiple sclerosis. J Neuroimmunol 2008;201-202:183-199.
45. Martin MP, Qi Y, Gao X, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007;39: 733-740. (Pubitemid 46848586)
46. Gaudieri S, DeSantis D, McKinnon E, et al. Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression. Genes Immun 2005;6:683-690. (Pubitemid 41741713)